{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:50:41Z","timestamp":1766497841287,"version":"3.48.0"},"reference-count":18,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"DOI":"10.1182\/bloodadvances.2025017770","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:58:13Z","timestamp":1759262293000},"page":"6340-6344","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Dual anti-CD19\/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-9778","authenticated-orcid":false,"given":"Malte","family":"Roerden","sequence":"first","affiliation":[{"name":"1Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-8537","authenticated-orcid":false,"given":"Luca","family":"Hensen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-3956","authenticated-orcid":false,"given":"Friederike","family":"Schwartz","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Reuss","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisha","family":"Weiss-Haug","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6430-051X","authenticated-orcid":false,"given":"Lennart","family":"Harland","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Faul","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-2805","authenticated-orcid":false,"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"2German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, A Partnership Between German Cancer Research Center and University Hospital T\u00fcbingen- University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"12","key":"2025122308361716800_bib1","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","article-title":"Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis","volume":"7","author":"Ragon","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2025122308361716800_bib2","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1016\/S2352-3026(22)00289-7","article-title":"Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Saleem","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"2025122308361716800_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41409-022-01867-4","article-title":"Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience","volume":"58","author":"Dreger","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2025122308361716800_bib4","first-page":"988.e1","article-title":"Anti-CD19 CAR-T cell therapy in elderly patients: multicentric real-world experience from GETH-TC\/GELTAMO","volume":"30","author":"Bail\u00e9n","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2025122308361716800_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025122308361716800_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2022-158934","article-title":"Outcome of 841 older patients (&gt;55 yrs) with newly diagnosed Ph\/BCR-ABL negative ALL prospectively treated according to pediatric-based, age-adapted GMALL protocols","volume":"140","author":"Goekbuget","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025122308361716800_bib7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025122308361716800_bib8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamaoncol.2024.0473","article-title":"Allogeneic CD19\/CD22 CAR T-cell therapy for B-cell acute lymphoblastic leukemia","volume":"10","author":"Phely","year":"2024","journal-title":"JAMA Oncol"},{"issue":"suppl 1","key":"2025122308361716800_bib9","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.1182\/blood-2024-200768","article-title":"Dual CD19\/CD22-targeting CAR-T cells for Richter transformation: a case series","volume":"144","author":"Hug","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025122308361716800_bib10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"24","key":"2025122308361716800_bib11","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"2025122308361716800_bib12","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025122308361716800_bib13","unstructured":"A phase I dose finding study of MB-CART2219.1 targeting CD19\/CD22 in adult and pediatric patients with relapsed\/refractory B-cell malignancies. Updated 1 April 2025. EU Clinical Trials identifier: EUCT 2024-516838-35-00. Accessed 6 October 2025. https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2024-516838-35-00?lang=en."},{"issue":"1","key":"2025122308361716800_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","article-title":"Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma","volume":"17","author":"Sesques","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2025122308361716800_bib15","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1016\/j.jtct.2023.12.227","article-title":"Identification of predictors of CRS and neurotoxicity duration after axicabtagene ciloleucel therapy","volume":"30","author":"Albittar","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2025122308361716800_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00277-023-05507-9","article-title":"Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy","volume":"103","author":"Winkelmann","year":"2024","journal-title":"Ann Hematol"},{"issue":"3","key":"2025122308361716800_bib17","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/10428194.2016.1207763","article-title":"Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide","volume":"58","author":"Rollison","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2025122308361716800_bib18","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2012-04-421883","article-title":"Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance","volume":"120","author":"Usmani","year":"2012","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6340\/2474731\/blooda_adv-2025-017770-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6340\/2474731\/blooda_adv-2025-017770-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:36:23Z","timestamp":1766496983000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6340\/547534\/Dual-anti-CD19-22-and-anti-BCMA-CAR-T-cell-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":18,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017770","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,11]]}}}